SAB Biotherapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SABS Nasdaq 2834 www.sabbiotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SAB Biotherapeutics, Inc.

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director - Jan 7th, 2026 6:00 am
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 6:00 am
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D - Dec 18th, 2025 6:00 am
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D - Dec 17th, 2025 6:00 am
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management - Dec 8th, 2025 6:00 am
SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last week - Nov 22nd, 2025 5:27 am
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights - Nov 13th, 2025 3:00 pm
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - Nov 4th, 2025 6:30 am
SAB BIO to Participate in Upcoming Investor Conferences - Nov 4th, 2025 6:00 am
SAB BIO Highlights Data in Multiple Presentations at EASD - Sep 19th, 2025 5:24 am
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - Sep 3rd, 2025 2:05 pm
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Aug 7th, 2025 8:00 am
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates - Aug 7th, 2025 5:30 am
SAB Biotherapeutics Raises $175 Million in Oversubscribed Private Placement; Shares Rise Pre-Bell - Jul 21st, 2025 6:07 am
SAB BIO Announces Oversubscribed $175 Million Private Placement - Jul 21st, 2025 5:30 am
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - May 9th, 2025 7:00 am
SAB BIO Reports Full Year 2024 Operating and Financial Results - Mar 31st, 2025 5:32 am
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - Jan 28th, 2025 5:00 am
3 Promising US Penny Stocks With At Least $20M Market Cap - Jan 27th, 2025 1:04 pm
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy - Jan 23rd, 2025 5:00 am